Compounded semaglutide and tirzepatide

FDA has reported dosing errors and adverse events involving compounded GLP-1 products. Concentration and labeling differences can matter. FDA also distinguishes semaglutide base from salt forms such as sodium or acetate. A familiar ingredient name is insufficient to establish the exact preparation. ¹

Approved oral semaglutide uses a specific formulation. A compounded capsule, liquid or troche requires its own evidence for absorption and clinical use; approved-tablet findings cannot simply be transferred. Ask which preparation was evaluated and whether the evidence matches the pharmacy product. ³

Do not infer oral or sublingual effectiveness from injectable tirzepatide trials. The reviewed Zepbound label describes injection. This draft does not establish the safety, effectiveness or legal eligibility of a particular compounded non-injectable preparation. ⁴

A shortage decision, enforcement policy or pharmacy license is not FDA approval of a compounded finished drug. Compounding can be appropriate in limited circumstances when an approved medicine cannot meet an identified patient's medical need, but the reason should be concrete and documented. FDA has warned that retatrutide and cagrilintide cannot be used in compounding under federal law. The legal and clinical questions must be answered for the exact substance, date, pharmacy type and patient situation. ^{1, 2}

Before first use, compare the patient name, active ingredient, ingredient form, concentration, route, beyond-use date, storage instructions and pharmacy contact on the container with the prescription. Injectable directions should state both the prescribed amount and the volume to measure on the supplied syringe. Terms such as units are unsafe without a device-specific explanation. Tablets, capsules, liquids and troches need formulation-specific directions; an approved oral label cannot supply missing instructions for a compounded dosage form. ^{1, 2, 3, 4}

Contact the dispensing pharmacy promptly if the vial, label, seal, color, particles or directions differ from what was expected. Severe abdominal pain, repeated vomiting, dehydration, fainting, breathing difficulty or facial or throat swelling needs urgent clinical assessment. Preserve the container and written directions if an error or adverse event occurs. Patients and clinicians can report quality problems and adverse events through FDA MedWatch. A report helps regulators identify patterns; it is separate from getting immediate medical care. ^{1, 2}

A new compounded refill can differ in concentration, container, syringe or instructions even when the ingredient name is unchanged. Compare every refill with the new prescription and pharmacy label before measuring it. Do not assume the same number of syringe units represents the same drug amount. Ask the pharmacy to state the amount in milligrams and corresponding volume in milliliters for the exact concentration supplied. ^{1, 2}